Placebo | Page 40 of 57 | SpiritIndia.com

COPD :: Inhaled corticosteroids reduce death in patients with copd

Prescription sleep aids may do little to improve the use of continuous positive airway pressure (CPAP) among patients with obstructive sleep apnea (OSA). A new study published in the November issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), finds that patients with OSA who were given prescription sleep aids were no more likely to use their CPAP machines than patients with OSA taking a placebo.

ADHD :: Columbia study examines ADHD’s role in smoking

Research has shown that most smoking in the US occurs among people who have psychiatric conditions, such as alcohol or drug abuse, major depression, anxiety and ADHD. Columbia University Medical Center researchers are recruiting smokers who have been diagnosed with ADHD to be part of a study that will help them quit smoking.

Hypertension :: Pine tree bark reduces side effects in hypertensive patients

A study published in the October journal of Clinical and Applied Thrombosis/Hemostasis shows Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree reduced edema, a typical side effect of antihypertensive medications, by 36 percent in patients taking these medications.

Asthma :: Approved Asthma Therapy SYMBICORT Improves Lung Function Safely and Effectively

Newly presented data indicate that treatment with SYMBICORT? (budesonide/formoterol fumarate dihydrate) inhalation aerosol results in significantly greater improvements in lung function, and a lower risk of asthma worsening episodes, compared to budesonide and/or formoterol used alone. In addition, data also showed that SYMBICORT was generally well-tolerated, with an adverse event profile similar to that of its individual components. These study results, involving patients with mild to moderate persistent asthma, were presented today at the American College of Allergy, Asthma & Immunology’s (ACAAI) annual scientific sessions held in Philadelphia on November 9-15, 2006.

Asthma :: PULMICORT RESPULES, budesonide inhalation suspension controls Asthma

Children treated with PULMICORT RESPULES? (budesonide inhalation suspension) either once or twice daily experienced a significantly greater increase in the percentage of asthma-control days compared to those receiving placebo. These results are being presented at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI), held in Philadelphia on November 9-15. Asthma-control days were defined as days when children were free of symptoms and did not use rescue medications during the day and night. Control of asthma symptoms during the day and night and reduction of the need for rescue medication is an important goal of asthma therapy in keeping with current National Asthma Education and Prevention Program (NAEPP) guidelines.

Heart Disease :: MEDAL – No increase in cardiovascular events with COX-2 inhibitor

Researchers in the randomized Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program found identical rates of thrombotic cardiovascular events in patients with osteoarthritis or rheumatoid arthritis treated with either the COX-2 inhibitor or the traditional NSAID. Christopher Cannon, M.D., an associate professor of medicine at Harvard Medical School, Boston, noted that this appears to contradict earlier observational studies associating COX-2 inhibitors with higher rates of thrombotic cardiovascular events.

Heart Disease :: WAFACS – Folic acid, B vitamins not supported

Results of a randomized trial of folic acid and B-vitamins in secondary prevention of cardiovascular events in women did not support their use as preventive agents against cardiovascular disease in women with established vascular disease or those at high risk.

Heart Disease :: Anticoagulant-antidote combo safe in humans

A novel anticoagulant and its complementary antidote was proven safe in the first human trial, say researchers from Duke University Medical Center, Durham, N.C. The system could be valuable, holding promise that clinicians could titrate anticoagulation, as it may not require monitoring.

Drug treats ‘water intoxication’ faster, more effectively

Results of the two largest studies on hyponatremia, SALT-1 and SALT-2, presented Nov. 14 at the American Heart Association’s Scientific Sessions in Chicago, found that the investigational drug tolvaptan treated hyponatremia ? water intoxication — faster and more effectively than available treatments.

Ankylosing Spondylitis :: Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years

Amgen (NASDAQ: AMGN) announced patients with ankylosing spondylitis who received treatment with Enbrel (R) (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy, according to data from an ongoing open-label, multinational, phase 4 extension study presented at the American College of Rheumatology scientific meeting. These results are consistent with an ENBREL phase 3 clinical trial at 24 weeks.